UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 15, 2012
INTERMUNE, INC.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation) |
0-29801 (Commission File Number) |
94-3296648 (IRS Employer Identification Number) |
3280 Bayshore Boulevard
Brisbane, CA 94005
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (415) 466-2200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Events. |
On March 15, 2012, InterMune, Inc. (InterMune) reported that Germanys Federal Joint Committee (G-BA) has announced its decision granting the additional benefit of Esbriet® (pirfenidone) in adults for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). Esbriets additional benefit was classified as stage 4 (not quantifiable benefit) in the rating system established under Germanys AMNOG pharmaceutical law. A non-quantifiable benefit means that the drug has an additional benefit, which will be defined in the future via experience in daily clinical use or clinical studies. Based on this, a stage of 1-3 will be assigned.
Under Germanys AMNOG law, the price charged by a manufacturer for a new pharmaceutical product is reviewed during the 12 months following the medicines launch. The current price for Esbriet in Germany will remain in effect until the pricing review is completed, which is expected by September 15, 2012.
In addition to Germany, Esbriet is commercially available in Austria, Norway, Denmark and Luxembourg.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 15, 2012 | INTERMUNE, INC. | |||||
By: | /s/ John C. Hodgman | |||||
John C. Hodgman | ||||||
Senior Vice President of Finance Administration and Chief Financial Officer |